David Loven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Loven has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Aaron Sulkes
Rabin Medical Center, Institute of Oncology, Petach Tikva, 49100, Israel
3 shared publicationsEyal Fenig
Rabin Medical Center, Institute of Oncology, Petach Tikva, 49100, Israel
2 shared publicationsA. Fishman
Department of Obstetrics and Gynecology, Sackler Faculty of Medicine, Sapir Medical Center, Kfar Saba
1 shared publication- Abhishek Mukherjee
Department of Genetics and Developmental Biology, Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa, Israel 1
1 shared publication Adam P. Steinmetz
Rabin Medical Center, Beilinson Campus
1 shared publicationAdi Shani
Institute of Oncology, Kaplan Medical Center, Rehovot, Israel
1 shared publication
Latest Publications
- Open Access
Breast Cancer-Derived Microparticles Reduce Cancer Cell Adhesion, an Effect Augmented by Chemotherapy
Tumor cell heterogeneity is primarily dictated by mutational changes, sometimes leading to clones that undergo a metastatic switch. However, little is known about tumor heterogeneity following chemotherapy perturbation. Here we studied the possible involvement of tumor-derived extracellular vesicles, often referred to as tumor-derived microparticles (TMPs), as mediators of the metastatic switch in the tumor microenvironment by hindering cell adhesion properties. Specifically, we show that highly metastatic or chemotherapy-treated breast cancer cells shed an increased number of TMPs compared to their respective controls. We found that these TMPs substantially reduce cell adhesion and disrupt actin filament structure, therefore increasing their biomechanical force pace, further implicating tumor cell dissemination as part of the metastatic cascade. Our results demonstrate that these pro-metastatic effects are mediated in part by CD44 which is highly expressed in TMPs obtained from highly metastatic cells or cells exposed to chemotherapy when compared to cells with low metastatic potential. Consequently, when we inhibited CD44 expression on TMPs by a pharmacological or a genetic approach, increased tumor cell adhesion and re-organized actin filament structure were observed. We also demonstrated that breast cancer patients treated with paclitaxel chemotherapy exhibited increased CD44-expressing TMPs. Overall, our study provides further insights into the role of TMPs in promoting metastasis, an effect which is augmented when tumor cells are exposed to chemotherapy.
Open AccessBreast Cancer-Derived Microparticles Reduce Cancer Cell Adhesion, an Effect Augmented by Chemotherapy
Tumor cell heterogeneity is primarily dictated by mutational changes, sometimes leading to clones that undergo a metastatic switch. However, little is known about tumor heterogeneity following chemotherapy perturbation. Here we studied the possible involvement of tumor-derived extracellular vesicles, often referred to as tumor-derived microparticles (TMPs), as mediators of the metastatic switch in the tumor microenvironment by hindering cell adhesion properties. Specifically, we show that highly metastatic or chemotherapy-treated breast cancer cells shed an increased number of TMPs compared to their respective controls. We found that these TMPs substantially reduce cell adhesion and disrupt actin filament structure, therefore increasing their biomechanical force pace, further implicating tumor cell dissemination as part of the metastatic cascade. Our results demonstrate that these pro-metastatic effects are mediated in part by CD44 which is highly expressed in TMPs obtained from highly metastatic cells or cells exposed to chemotherapy when compared to cells with low metastatic potential. Consequently, when we inhibited CD44 expression on TMPs by a pharmacological or a genetic approach, increased tumor cell adhesion and re-organized actin filament structure were observed. We also demonstrated that breast cancer patients treated with paclitaxel chemotherapy exhibited increased CD44-expressing TMPs. Overall, our study provides further insights into the role of TMPs in promoting metastasis, an effect which is augmented when tumor cells are exposed to chemotherapy.
- 1 January 2009
- Published by Wiley in European Journal of Cancer Care
- Vol. 18 (1) , 78-83
Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel
Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity. This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study. Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P). Patients were evaluated by neurological examinations, questionnaires and sensory-motor nerve conduction studies. There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011). Also the frequency of abnormal electro-diagnostic findings showed similarity between the two groups (G: 7/23 = 30.4%; P: 6/20 = 30%). This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.
- 1 January 2009
- Published by Wiley in European Journal of Cancer Care
- Vol. 18 (1) , 78-83
Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel
Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity. This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study. Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P). Patients were evaluated by neurological examinations, questionnaires and sensory-motor nerve conduction studies. There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011). Also the frequency of abnormal electro-diagnostic findings showed similarity between the two groups (G: 7/23 = 30.4%; P: 6/20 = 30%). This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.
- Open Access
- 1 January 2008
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (1) , 104-109
Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients
Metronomic low-dose chemotherapy regimen was found to have an antiangiogenic effect in tumors. However, its effect on levels of circulating pro-angiogenic and anti-angiogenic factors is not fully explored. Materials and methods. The levels of both VEGF and PDGF-BB were measured in three time points, in the serum of 32 rectal carcinoma patients receiving daily reduced-dose/continuous capecitabine in combination with preoperative pelvic irradiation. Results. We found a significant decrease in VEGF and PDGF-BB serum levels during the combination treatment (pDiscussion. These results suggest that combined chemo-irradiation affect levels of pro-angiogenic factors during treatment, and may reflect an anti-angiogenic window induced during this treatment. The potential implications of this inducible phenomenon, including a possible clinical benefit from the administration of long lasting metronomic chemotherapy immediately following combined chemo-irradiation, would warrant further investigation.
- 1 January 2008
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (1) , 104-109
Open AccessDaily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients
Metronomic low-dose chemotherapy regimen was found to have an antiangiogenic effect in tumors. However, its effect on levels of circulating pro-angiogenic and anti-angiogenic factors is not fully explored. Materials and methods. The levels of both VEGF and PDGF-BB were measured in three time points, in the serum of 32 rectal carcinoma patients receiving daily reduced-dose/continuous capecitabine in combination with preoperative pelvic irradiation. Results. We found a significant decrease in VEGF and PDGF-BB serum levels during the combination treatment (pDiscussion. These results suggest that combined chemo-irradiation affect levels of pro-angiogenic factors during treatment, and may reflect an anti-angiogenic window induced during this treatment. The potential implications of this inducible phenomenon, including a possible clinical benefit from the administration of long lasting metronomic chemotherapy immediately following combined chemo-irradiation, would warrant further investigation.
- 16 May 2006
- Published by Wiley in Journal of Surgical Oncology
- Vol. 93 (7) , 529-533
Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5‐fluorouracil
Background We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5‐fluorouracil (5‐FU) in the preoperative chemoradiation treatment of patients with rectal cancer. Patients and Methods The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5‐FU, were reviewed, and the outcome of the groups was compared. Results There was no statistically significant difference in the complete pathological response rate between the capecitabine and the 5‐FU groups (30% vs. 17%, P = 0.15). The downstaging rate was higher in the capecitabine group (77% vs. 50%, P = 0.009). Toxicity was mild in both groups. The rate of Grade 3 gastrointestinal toxicity was similar in the two groups (diarrhea 2% vs. 4%, proctitis 5% vs. 7%), except for one patient in the 5‐FU group (2%) who developed a rectovaginal fistula. In the capecitabine group, one patient (2%) had Grade 3 hand‐foot syndrome, and another had an acute myocardial infarction. In the 5‐FU group, two patients (4%) had Grade 3 hematological toxicity, and three (6%) had complications from Port‐a‐Cath insertion. Conclusion Preoperative chemoradiation with oral capecitabine appears to be safe and well tolerated, and at least as good as continuous 5‐FU. J. Surg. Oncol. 2006;93:529–533.
- 16 May 2006
- Published by Wiley in Journal of Surgical Oncology
- Vol. 93 (7) , 529-533
Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5‐fluorouracil
Background We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5‐fluorouracil (5‐FU) in the preoperative chemoradiation treatment of patients with rectal cancer. Patients and Methods The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5‐FU, were reviewed, and the outcome of the groups was compared. Results There was no statistically significant difference in the complete pathological response rate between the capecitabine and the 5‐FU groups (30% vs. 17%, P = 0.15). The downstaging rate was higher in the capecitabine group (77% vs. 50%, P = 0.009). Toxicity was mild in both groups. The rate of Grade 3 gastrointestinal toxicity was similar in the two groups (diarrhea 2% vs. 4%, proctitis 5% vs. 7%), except for one patient in the 5‐FU group (2%) who developed a rectovaginal fistula. In the capecitabine group, one patient (2%) had Grade 3 hand‐foot syndrome, and another had an acute myocardial infarction. In the 5‐FU group, two patients (4%) had Grade 3 hematological toxicity, and three (6%) had complications from Port‐a‐Cath insertion. Conclusion Preoperative chemoradiation with oral capecitabine appears to be safe and well tolerated, and at least as good as continuous 5‐FU. J. Surg. Oncol. 2006;93:529–533.
- 1 March 2004
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 67 (1-2) , 221-226
Non-Resectable Slow-Growing Meningiomas Treated by Hydroxyurea
Purpose: To test the benefit of hydroxyurea in the treatment of recurrent and non-resectable slow-growing meningiomas. Methods:Twelve patients with regrowing non-malignant meningiomas, were enrolled...
- 1 March 2004
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 67 (1-2) , 221-226
Non-Resectable Slow-Growing Meningiomas Treated by Hydroxyurea
Purpose: To test the benefit of hydroxyurea in the treatment of recurrent and non-resectable slow-growing meningiomas. Methods:Twelve patients with regrowing non-malignant meningiomas, were enrolled...